Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.47 |
| ▸ | ABL1 | P00519 | 5/20 | 0.47 |
| ▸ | ABL2 | P42684 | 5/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13087283 | 0.76 | EGFR (0.53) | EGFRABL1ABL2PRKCATRPA1 | |
| SCHEMBL24061044 | 0.75 | EGFR (0.51) | EGFRABL1ABL2PRKCATRPA1 | |
| SCHEMBL1895093 | 0.73 | EGFR (0.55) | EGFRABL1ABL2PRKCATRPA1 | |
| SCHEMBL17032328 | 0.70 | AKT1 (0.42) | TRPA1IRAK4 | |
| SCHEMBL14156722 | 0.70 | EGFR (0.54) | EGFRABL1ABL2PRKCATRPA1 | |
| SCHEMBL10220261 | 0.67 | LIMK1 (0.58) | — | |
| SCHEMBL19185358 | 0.67 | IRAK4 (0.41) | TRPA1IRAK4 | |
| SCHEMBL22907455 | 0.67 | CCR4 (0.39) | — | |
| SCHEMBL14329105 | 0.67 | PARP1 (0.33) | — | |
| SCHEMBL21392272 | 0.67 | TRPA1 (0.42) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292189-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292189-A1 | LIM KINASE INHIBITORS | LIMK1, LIMK2, LIMA1 | EGFR 4394/4885ABL1 3096/4885ABL2 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.